A novel pan-negative-gating modulator of KCa2/3 channels, fluoro-di-benzoate, RA-2, inhibits Endothelium-derived hyperpolarization–type relaxation in coronary artery and produces bradycardia in vivo
Resumen: Small/intermediate conductance KCa channels (KCa2/3) are Ca2+/calmodulin regulated K+ channels that produce membrane hyperpolarization and shape neurologic, epithelial, cardiovascular, and immunologic functions. Moreover, they emerged as therapeutic targets to treat cardiovascular disease, chronic inflammation, and some cancers. Here, we aimed to generate a new pharmacophore for negative-gating modulation of KCa2/3 channels. We synthesized a series of mono- and dibenzoates and identified three dibenzoates [1,3-phenylenebis(methylene) bis(3-fluoro-4-hydroxybenzoate) (RA-2), 1,2-phenylenebis(methylene) bis(3-fluoro-4-hydroxybenzoate), and 1,4-phenylenebis(methylene) bis(3-fluoro-4-hydroxybenzoate)] with inhibitory efficacy as determined by patch clamp. Among them, RA-2 was the most drug-like and inhibited human KCa3.1 with an IC50 of 17 nM and all three human KCa2 subtypes with similar potencies. RA-2 at 100 nM right-shifted the KCa3.1 concentration-response curve for Ca2+ activation. The positive-gating modulator naphtho[1,2-d]thiazol-2-ylamine (SKA-31) reversed channel inhibition at nanomolar RA-2 concentrations. RA-2 had no considerable blocking effects on distantly related large-conductance KCa1.1, Kv1.2/1.3, Kv7.4, hERG, or inwardly rectifying K+ channels. In isometric myography on porcine coronary arteries, RA-2 inhibited bradykinin-induced endothelium-derived hyperpolarization (EDH)–type relaxation in U46619-precontracted rings. Blood pressure telemetry in mice showed that intraperitoneal application of RA-2 (=100 mg/kg) did not increase blood pressure or cause gross behavioral deficits. However, RA-2 decreased heart rate by ˜145 beats per minute, which was not seen in KCa3.1-/- mice. In conclusion, we identified the KCa2/3–negative-gating modulator, RA-2, as a new pharmacophore with nanomolar potency. RA-2 may be of use to generate structurally new types of negative-gating modulators that could help to define the physiologic and pathomechanistic roles of KCa2/3 in the vasculature, central nervous system, and during inflammation in vivo.
Idioma: Inglés
DOI: 10.1124/mol.114.095745
Año: 2015
Publicado en: MOLECULAR PHARMACOLOGY 87, 2 (2015), 338-348
ISSN: 0026-895X

Factor impacto: 3.931 (2015)
Categ. JCR: PHARMACOLOGY & PHARMACY rank: 45 / 255 = 0.176 (2015) - Q1 - T1
Financiación: info:eu-repo/grantAgreement/ES/DGA/GAE-102
Financiación: info:eu-repo/grantAgreement/ES/DGA/GIPASC-B105
Financiación: info:eu-repo/grantAgreement/EUR/FP7/PEOPLE-321721
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/RD12-0042-0014
Tipo y forma: Article (Published version)
Área (Departamento): Química Orgánica (Departamento de Química Orgánica)
Exportado de SIDERAL (2018-02-28-10:17:24)

Este artículo se encuentra en las siguientes colecciones:
articulos > articulos-por-area > quimica_organica

 Notice créée le 2018-02-22, modifiée le 2018-02-28

Versión publicada:
Évaluer ce document:

Rate this document:
(Pas encore évalué)